2023
Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9).
Barlesi F, Goldberg S, Mann H, Gopinathan A, Newton M, Aggarwal C. Phase 3 study of durvalumab combined with oleclumab or monalizumab in patients with unresectable stage III NSCLC (PACIFIC-9). Journal Of Clinical Oncology 2023, 41: tps8610-tps8610. DOI: 10.1200/jco.2023.41.16_suppl.tps8610.Peer-Reviewed Original ResearchUnresectable stage III NSCLCStage III NSCLCBlinded independent central reviewProgression-free survivalIII NSCLCConsolidation therapyNumerically higher objective response rateBind to HLA-EHigher objective response rateInhibition of natural killerProlonged progression-free survivalCD8+ T cellsResponse rateDurvalumab consolidation therapyObjective response ratePD-L1 expressionPD-L1 statusPD-L1 inhibitionPromote antitumor immunityDuration of responsePhase 2 trialWHO performance statusIndependent central reviewPhase 3 studyMonths of treatment
2017
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Thress K, Markovets A, Barrett J, Chmielecki J, Goldberg S, Shepherd F, Vowler S, Oxnard G. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal Of Clinical Oncology 2017, 35: 9018-9018. DOI: 10.1200/jco.2017.35.15_suppl.9018.Peer-Reviewed Original ResearchMedian progression-free survivalPlasma EGFR mutationsDetectable EGFR mutationsEGFR mutationsClinical outcomesOverall median progression-free survivalResponse ratePlasma samplesDurable response rateHeterogeneous resistance mechanismsObjective response ratePositive advanced NSCLCProgression-free survivalEGFR-TKI therapyPredictors of outcomeTyrosine kinase inhibitorsBaseline genotypingEvaluable baselinePositive genotypingAdvanced NSCLCPositive NSCLCCombination therapyEGFR-TKIsOsimertinib therapyComplete clearance